Recently, according to an announcement issued by the Ministry of Agriculture and Rural Affairs of the People's Republic of China on JAN.06, 2026, two new veterinary drug products co-developed by Jinan GSY Biotechnology Co., Ltd. have successfully passed approval. These include Category II new veterinary drug Fluralaner Chewable Tablets and Category V new veterinary drug Prednisolone Tablets. This marks a new breakthrough for the company in the fields of innovative R&D and clinical treatment for pet medications.

According to Announcement No. 986 of the Ministry of Agriculture and Rural Affairs, Fluralaner Chewable Tablets have been approved as a Category II new veterinary drug. This product is indicated for the treatment of flea (Ctenocephalides cati) and tick (Dermacentor reticulatus and Ixodes persulcatus) infestations on dogs, providing a new standardized medication option for the prevention and control of external parasites in canine animals.

Meanwhile, according to Announcement No. 981 of the Ministry of Agriculture and Rural Affairs, Prednisolone Tablets have been approved as a Category V new veterinary drug. This product is primarily indicated for the treatment of allergic and inflammatory diseases in dogs. It demonstrates broad clinical applicability, covering dermatological conditions, allergic reactions, ocular disorders, otic issues, musculoskeletal system diseases, and certain chronic or recurrent diseases of unknown etiology. It provides significant support for the comprehensive management of canine diseases.

The simultaneous approval of these two new veterinary drugs further enriches Jinan GSY Biotechnology Co., Ltd.'s product portfolio in the pet pharmaceutical sector. This achievement reflects the company's sustained accumulation and steady progress in R&D innovation, quality management, and regulatory registration. Moving forward, the company will continue to focus on clinical needs in pet pharmaceuticals, driving the development and application of high-quality veterinary products. By continuously enhancing product value and service standards, it aims to contribute to pet health and the high-quality development of the industry.